Source: Medicines Authority (MT) Revision Year: 2021 Publisher: URSAPHARM Arzneimittel GmbH, Industriestraße, 66129 Saarbrücken, Germany Tel.: +49 (0)6805/92 92-0 Fax: +49 (0)6805/92 92-88 e-mail: info@ursapharm.de
Posiforlid 20 mg/g eye ointment.
Pharmaceutical Form |
---|
Eye ointment. Ochre, homogenous ointment. |
1 g of eye ointment contains 20 mg Bibrocathol.
Excipient(s) with known effect: Contains wool fat.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Bibrocathol |
Bibrocathol is a bismuth-containing substance which acts as antiseptic, adstringent and secretion inhibitng agent on mucous membranes and wounds. The mechanism of action is explained by its phenolic molecular structure consisting of tetrabromopyrocatechol and bismuth hydroxide that causes the precipitation of proteins and the shrinking of superficial layers of tissue. These activities result in the formation of a protective membrane against pathogenic invasion and non-specifically inhibit inflammation and secretion. |
List of Excipients |
---|
White petrolatum |
Aluminium tube with inner protective lacquer made of epoxy phenolic resin, high-density polyethylene nozzle and screw cap.
The following packsize is available: Folding carton with one tube of 5 g.
URSAPHARM Arzneimittel GmbH, Industriestraße, 66129 Saarbrücken, Germany
Tel.: +49 (0)6805/92 92-0
Fax: +49 (0)6805/92 92-88
e-mail: info@ursapharm.de
MA063/01101
Date of first authorisation: 5th November 2021
Date of latest renewal: N/A
Drug | Countries | |
---|---|---|
POSIFORLID | Malta |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.